Pluvicto
Active Awarded Last action
- Contract number
- 36C25725N0376
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $857,357
Award facts
- Contract value 100% obligated
- $857,356.50 Current and potential, with all options
- Completion date 67% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $445,825 | |
| Supplemental Agreement for work within scope | -$20,448 | |
| Original award | $431,979 |
About this award
Novartis Pharmaceuticals Corporation received a $857,356.50 firm fixed-price delivery order for PLUVICTO (Lutetium Lu-177 Vipivotide Tetra), a specialized radiopharmaceutical cancer therapy, from Veterans Integrated Service Network 17 through the Department of Veterans Affairs. The delivery order, designated OY1, was awarded on July 1, 2025, with an ultimate completion date of June 30, 2027, and will be performed at the company's East Hanover, New Jersey facility. No small business set-aside was used in this procurement. This delivery order is issued under Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which establishes the terms and conditions for the supply of pharmaceutical products to federal healthcare systems.
This award represents one of multiple delivery orders Novartis has received across various Veterans Integrated Service Networks for PLUVICTO and other specialized oncology and radiopharmaceutical treatments. The company serves as a major federal supplier of advanced cancer therapies and nuclear medicine products to the Department of Veterans Affairs and Defense Health Agency, with contract awards spanning multiple facilities nationwide. As a large, foreign-owned pharmaceutical manufacturer, Novartis competes directly in the federal marketplace without small business protections and maintains significant indefinite delivery vehicles, including a $7.48 million blanket purchase agreement with VISN 10 for PLUVICTO procurement extending through September 2030.
Quick answers
Who was awarded contract 36C25725N0376?
36C25725N0376 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 17 (Veterans Health Administration) on July 1, 2025.
How much is contract 36C25725N0376 worth?
The government has obligated $857,357 on 36C25725N0376.
Is contract 36C25725N0376 an order under another contract?
Yes. 36C25725N0376 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25725N0376 competed?
The extent of competition for 36C25725N0376 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award